At least one major Chinese supplier is being tapped to relieve a shortage of certain drugs in the US despite rising Beijing-Washington tensions, but China may be increasingly unwilling to co-operate amid its own shifting economic priorities, increasingly introspective policies and some shortages of its own.
In early June, an announcement from the US Food and Drug Administration highlighted an urgent need to secure continued supplies of certain drugs. The agency noted that more than 130 products, including 14 treatments for cancer, were in short supply.
On 13 June 13, the Health Subcommittee of the US House of Representatives then held a public hearing to highlight the issue, during which it was reported that more than 90% of members of a cancer treatment
Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.
InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.
Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.
Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.
InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.
Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.
Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.
